MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Cost of Revenue 2011-2026 | SNOA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.82 M | 7.99 M | 8.8 M | 8.64 M | 12.1 M | 9.81 M | 10.1 M | 9.35 M | 7.16 M | 6.72 M | 6.57 M | 5.27 M | 4.71 M | 4.03 M | 3.61 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | 3.61 M | 7.57 M |
Quarterly Cost of Revenue Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.7 M | 3.48 M | 2.55 M | - | 2.29 M | 2.22 M | 2.08 M | - | 1.68 M | 1.74 M | 2.22 M | - | 2.11 M | 1.8 M | 2.34 M | - | 1.7 M | 6.43 M | 4.73 M | - | 2.94 M | 2.94 M | 3.27 M | 3.51 M | 2.39 M | 2.52 M | 2.67 M | 2.34 M | 2.43 M | 2.43 M | 2.51 M | - | 2.48 M | 2.48 M | 2.07 M | - | 1.66 M | 5.08 M | 3.42 M | - | 2.03 M | 5.12 M | 3.77 M | - | 1.56 M | 4.58 M | 3.02 M | - | 1.18 M | 3.74 M | 2.56 M | - | 1.07 M | 3.56 M | 32 K | - | 938 K | 2.81 M | 20 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.43 M | 20 K | 2.62 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.07 | -0.47 % | $ 115 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.55 | -0.97 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 11.92 | 1.24 % | $ 847 M | USA |
 |
Evolus
EOLS
|
84 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.38 | -3.17 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.86 | -4.67 % | $ 377 M | USA |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 11.38 | -7.97 % | $ 1.58 B | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.53 | 0.33 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
Veru
VERU
|
11 M | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 15.09 | -3.89 % | $ 18.1 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.79 | -2.48 % | $ 3.41 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Tilray
TLRY
|
480 M | $ 7.37 | -2.97 % | $ 4.55 B | Canada |